Brokerages Set Certara, Inc. (NASDAQ:CERT) Price Target at $15.42

Shares of Certara, Inc. (NASDAQ:CERT - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eight research firms that are covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $15.83.

CERT has been the topic of several recent analyst reports. Robert W. Baird decreased their price target on Certara from $18.00 to $13.00 and set a "neutral" rating on the stock in a research note on Tuesday, November 5th. TD Cowen assumed coverage on shares of Certara in a research note on Thursday. They issued a "buy" rating and a $16.00 target price on the stock. William Blair reiterated a "market perform" rating on shares of Certara in a research report on Thursday. Stephens restated an "overweight" rating and issued a $17.00 price target on shares of Certara in a research report on Thursday. Finally, Barclays raised their price objective on shares of Certara from $12.00 to $13.00 and gave the stock an "equal weight" rating in a report on Friday.

Certara Price Performance

CERT traded down $0.04 during midday trading on Thursday, reaching $11.94. 1,899,266 shares of the company's stock were exchanged, compared to its average volume of 965,527. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The business has a 50-day simple moving average of $12.45 and a two-hundred day simple moving average of $11.63. The firm has a market capitalization of $1.92 billion, a price-to-earnings ratio of -59.70, a price-to-earnings-growth ratio of 9.29 and a beta of 1.57. Certara has a one year low of $9.41 and a one year high of $19.87.

Remove Ads

Institutional Trading of Certara

A number of hedge funds and other institutional investors have recently modified their holdings of CERT. Venturi Wealth Management LLC increased its stake in shares of Certara by 839.1% in the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company's stock valued at $30,000 after buying an additional 2,509 shares during the period. Wells Fargo & Company MN boosted its holdings in Certara by 48.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock valued at $34,000 after acquiring an additional 1,047 shares during the last quarter. Blue Trust Inc. increased its position in Certara by 112.3% in the third quarter. Blue Trust Inc. now owns 3,925 shares of the company's stock worth $46,000 after purchasing an additional 2,076 shares during the period. Johnson Financial Group Inc. bought a new stake in Certara during the 4th quarter worth about $47,000. Finally, KBC Group NV lifted its position in Certara by 48.2% during the 3rd quarter. KBC Group NV now owns 4,873 shares of the company's stock valued at $57,000 after purchasing an additional 1,584 shares during the period. Institutional investors and hedge funds own 73.96% of the company's stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.